Lilly Endowment sells $1.65 billion in Eli Lilly stock

INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), disclosed a significant sale of the company’s common stock. According to a recent SEC filing, the endowment sold a total of 64,444 shares on February 24, 2025. The shares were sold across multiple transactions, with prices ranging from $877.311 to $878,401.00 per share, resulting in a total transaction value of approximately $1.65 billion.

Following this transaction, Lilly Endowment retains ownership of 96,467,741 shares in the pharmaceutical giant, which now commands a market capitalization of $810.92 billion. The sale underscores the endowment’s ongoing management of its investment portfolio, while Eli Lilly continues to be a pivotal player in the life sciences sector, maintaining dividend payments for 55 consecutive years with a 15.38% dividend growth in the last twelve months. InvestingPro subscribers have access to 18 additional key insights about Eli Lilly, including detailed financial health metrics and growth projections.

In other recent news, Eli Lilly and Company has made significant strides in its business operations. The company has successfully issued $6 billion in new debt across six tranches, with maturities spanning from 2028 to 2065, and plans to use the proceeds for general corporate purposes. Additionally, Eli Lilly has acquired Organovo’s FXR program for inflammatory bowel disease treatment, enhancing its portfolio in this therapeutic area. The acquisition includes worldwide rights to the commercial and intellectual property aspects of the FXR program, further strengthening Eli Lilly’s research capabilities.

In another development, Eli Lilly has launched new Zepbound vials and reduced prices under its Self Pay Journey Program. This initiative aims to make obesity treatment more affordable by offering various dosage options at lower prices. Analysts from Bernstein have maintained an Outperform rating on Eli Lilly, with a price target of $1,100, following the resolution of a semaglutide shortage that is expected to benefit Eli Lilly’s diabetes drugs, Mounjaro and Zepbound. The firm’s strategic moves, including the debt issuance and product launches, reflect its commitment to expanding its market presence and enhancing patient access to its therapies. These recent developments highlight Eli Lilly’s ongoing efforts to innovate and adapt in the competitive pharmaceutical landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.